MetaCap

Fulcrum Therapeutics (FULC) vs Galectin Therapeutics (GALT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Galectin Therapeutics (GALT) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 49.7% versus a loss of 67.3%. Over five years, GALT leads with a +4.7% price change compared with -75.5% for FULC. Fulcrum Therapeutics is the larger company by market cap ($281.8 million vs $271.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FULC-67.32%GALT-49.72%
+34%-21%-77%
Nov 21, 20251 yearNov 20, 2026
FULC-78.47%GALT0.00%
+143%+23%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FULC versus GALT key metrics
MetricFULCGALT
Share price$3.69$2.69
Market cap$281.85M$271.35M
1-day change-0.54%-4.27%
YTD return-67.37%-35.34%
1-year return-67.32%-49.72%
5-year return-75.50%+4.67%
EPS (TTM)$-1.04$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-74.88M$-30.84M
52-week high$15.74$7.13
52-week low$2.83$2.03
Distance from 52-week high-76.56%-62.27%
Analyst consensusholdstrong_buy
Avg. price target upside-0.54%+308.92%
Average volume1.37M252.31K
Shares outstanding76.38M100.88M
Employees559
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GALT has outperformed FULC by 17.6 percentage points over the past year.

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

FULC vs GALT FAQ

Which is bigger, Fulcrum Therapeutics or Galectin Therapeutics?

Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.85M compared with $271.35M for Galectin Therapeutics (GALT).

Which stock has performed better over the past year, FULC or GALT?

GALT returned -49.72% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.

Are Fulcrum Therapeutics and Galectin Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons